Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Year: 2019
Type: article
Abstract: Patients with type 2 diabetes mellitus are at high risk of developing heart failure (HF).1 Sodium glucose co-transporter 2 (SGLT2) inhibitors have been demonstrated, in large scale trials, to reduce the risk of HF events in patients with type 2 diabetes deemed to be at high risk based on established cardiovascular disease or multiple risk factors.2-4 However, it is unclear whether benefits are experienced across the broad spectrum of HF patients that includes those with preserved (HFpEF) as well as reduced ejection fraction (HFrEF).
Source: Circulation
Institutions: The University of Sydney, Royal North Shore Hospital, UNSW Sydney, The George Institute for Global Health, Linköping University, Region Östergötland, Janssen Research & Development (United States), Stanford Medicine, Stanford University, University Medical Center Groningen, University of Groningen, University of Oxford, Oxford Centre for Diabetes, Endocrinology and Metabolism, The George Institute for Global Health, Imperial College London
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funders: Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Gilead Sciences, Heart Research Australia, European Foundation for the Study of Diabetes, Novo Nordisk, Astellas Pharma, European Association for the Study of Diabetes, Servier, Mitsubishi Tanabe Pharma Corporation, George Institute for Global Health, Stanford Bio-X, Medical Research Council, National Health and Medical Research Council, Relypsa
OpenAlex ID: W2921779932
